Related Experiment Video

Updated: May 23, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Inhibition of TGFβ signaling and its implications in anticancer treatments

I Calone1, S Souchelnytskyi

  • 1Department of Oncology-Pathology, Karolinska Biomics Center, Karolinska Institute, Stockholm, Sweden. I.Calone@hotmail.fr

Experimental Oncology
|March 29, 2012
PubMed

Insights

Transforming growth factor-β (TGFβ) exhibits dual roles in cancer, acting as a suppressor early on and a promoter later. This review explores TGFβ signaling inhibition strategies for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Transforming growth factor-β (TGFβ) is a key regulator in tumorigenesis.
  • TGFβ displays a dual role in cancer: tumor suppression in early stages and tumor promotion in later stages.
  • The complex behavior of TGFβ in cancer necessitates understanding its signaling pathways for therapeutic development.

Purpose of the Study:

  • To review the multifaceted role of TGFβ in cancer progression and metastasis.
  • To elucidate the mechanisms by which TGFβ signaling contributes to carcinogenesis.
  • To explore and evaluate therapeutic strategies targeting TGFβ signaling pathways for cancer treatment.

Main Methods:

  • Review of existing literature on TGFβ signaling in cancer.
  • Analysis of therapeutic strategies targeting TGFβ at ligand, receptor, and intracellular levels.
  • Examination of clinical trial data for TGFβ inhibitors in cancer therapy.

Main Results:

  • TGFβ signaling is implicated in both tumor suppression and promotion, depending on the cancer stage.
  • Inhibitors targeting TGFβ signaling have shown promise in preclinical and clinical settings.
  • Therapeutic strategies are being developed at multiple levels of the TGFβ pathway.

Conclusions:

  • Targeting TGFβ signaling pathways represents a promising therapeutic approach for various cancers.
  • Further research into the dualistic role of TGFβ is crucial for optimizing cancer treatment strategies.
  • Inhibitors of TGFβ signaling are advancing through clinical trials with encouraging outcomes.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...